Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig's Disease) Clinical Trials

Find Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig's Disease) Clinical Trials Near You

VOICE: An Early Feasibility Study of a Precise Robotically Implanted Brain-Computer Interface for Communication Restoration

Status: Recruiting
Location: See location...
Intervention Type: Device
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

The VOICE Study is an early feasibility study to evaluate the initial clinical safety and efficacy of the N1 and R1 Systems device design concept in providing an ability to communicate. The Neuralink N1 Implant is intended to provide the ability to communicate to individuals with severe and irreversible speech production impairment. It is indicated for adults with neurological conditions of the central speech pathways who have impaired upper limb function. The N1 Implant is a skull-mounted, wireless, rechargeable implant connected to electrode threads that are implanted in the brain by the R1 Robot, a robotic electrode thread inserter.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 22
Maximum Age: 75
Healthy Volunteers: f
View:

⁃ Adults with diagnosis of ALS, PLS, stroke, or Spinal Cord Injury who have severe speech impairment and impaired upper limb function.

• Life expectancy ≥ 12 months.

• Ability to communicate in English

• Presence of a stable caregiver

Locations
United States
Texas
The University of Texas Southwestern Medical Center
RECRUITING
Dallas
Contact Information
Primary
Neuralink Clinical Team
voice-study@neuralink.com
+1 (650) 250-0520
Time Frame
Start Date: 2025-10-03
Estimated Completion Date: 2031-10
Participants
Target number of participants: 6
Treatments
Experimental: Neuralink N1 Implant and R1 Robot
Implantation of the N1 Implant by the R1 Robot.
Sponsors
Leads: Neuralink Corp

This content was sourced from clinicaltrials.gov